| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dementia | 27 | 2023 | 565 | 3.050 |
Why?
|
| Alzheimer Disease | 40 | 2023 | 2115 | 2.760 |
Why?
|
| Aspirin | 24 | 2023 | 83 | 2.530 |
Why?
|
| Aged | 113 | 2023 | 9076 | 2.430 |
Why?
|
| Aging | 31 | 2022 | 1550 | 2.360 |
Why?
|
| Depression | 14 | 2022 | 444 | 2.110 |
Why?
|
| Aged, 80 and over | 80 | 2023 | 4830 | 1.940 |
Why?
|
| Cognition | 20 | 2023 | 1337 | 1.900 |
Why?
|
| Disabled Persons | 12 | 2022 | 122 | 1.860 |
Why?
|
| Cardiovascular Diseases | 10 | 2023 | 324 | 1.640 |
Why?
|
| Cognitive Dysfunction | 19 | 2023 | 1065 | 1.620 |
Why?
|
| Female | 102 | 2023 | 15250 | 1.620 |
Why?
|
| Humans | 132 | 2023 | 27134 | 1.600 |
Why?
|
| Male | 98 | 2023 | 14810 | 1.580 |
Why?
|
| Family | 4 | 2021 | 102 | 1.470 |
Why?
|
| Critical Illness | 3 | 2022 | 120 | 1.340 |
Why?
|
| Physicians | 2 | 2020 | 124 | 1.140 |
Why?
|
| Brain | 14 | 2021 | 1648 | 1.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2021 | 55 | 1.070 |
Why?
|
| Hemoglobins | 3 | 2012 | 33 | 1.040 |
Why?
|
| Cognition Disorders | 13 | 2018 | 986 | 1.010 |
Why?
|
| Independent Living | 18 | 2023 | 322 | 0.990 |
Why?
|
| Cohort Studies | 32 | 2023 | 1901 | 0.990 |
Why?
|
| Neuropsychological Tests | 22 | 2022 | 1197 | 0.970 |
Why?
|
| Blood Pressure | 6 | 2021 | 195 | 0.960 |
Why?
|
| Residence Characteristics | 6 | 2018 | 215 | 0.960 |
Why?
|
| Tissue Donors | 4 | 2020 | 79 | 0.940 |
Why?
|
| Hypertension | 6 | 2021 | 193 | 0.860 |
Why?
|
| Critical Care | 3 | 2022 | 122 | 0.850 |
Why?
|
| Chronic Disease | 3 | 2020 | 422 | 0.840 |
Why?
|
| Anxiety | 2 | 2022 | 156 | 0.830 |
Why?
|
| Activities of Daily Living | 10 | 2021 | 597 | 0.820 |
Why?
|
| Motor Activity | 4 | 2012 | 321 | 0.800 |
Why?
|
| Antihypertensive Agents | 6 | 2021 | 54 | 0.720 |
Why?
|
| Risk Factors | 25 | 2023 | 2331 | 0.710 |
Why?
|
| Intensive Care Units | 2 | 2022 | 265 | 0.700 |
Why?
|
| Hospitalization | 6 | 2021 | 300 | 0.680 |
Why?
|
| Australia | 16 | 2022 | 42 | 0.660 |
Why?
|
| United States | 24 | 2022 | 2056 | 0.650 |
Why?
|
| Patient Advocacy | 1 | 2019 | 13 | 0.650 |
Why?
|
| Middle Aged | 24 | 2021 | 9016 | 0.620 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 97 | 0.620 |
Why?
|
| Tracheostomy | 1 | 2018 | 24 | 0.610 |
Why?
|
| Prospective Studies | 15 | 2023 | 1774 | 0.610 |
Why?
|
| Mortality, Premature | 1 | 2018 | 6 | 0.600 |
Why?
|
| Stress, Psychological | 1 | 2021 | 234 | 0.600 |
Why?
|
| Communication | 1 | 2019 | 106 | 0.600 |
Why?
|
| Ventilator Weaning | 1 | 2018 | 35 | 0.590 |
Why?
|
| Patient Care Team | 1 | 2019 | 119 | 0.580 |
Why?
|
| Frailty | 3 | 2022 | 34 | 0.570 |
Why?
|
| Caregivers | 3 | 2019 | 197 | 0.560 |
Why?
|
| Volunteers | 1 | 2017 | 4 | 0.550 |
Why?
|
| Longitudinal Studies | 19 | 2023 | 1369 | 0.550 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2023 | 47 | 0.540 |
Why?
|
| Mass Screening | 1 | 2018 | 173 | 0.540 |
Why?
|
| Functional Food | 1 | 2017 | 2 | 0.540 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 216 | 0.530 |
Why?
|
| Social Networking | 1 | 2016 | 11 | 0.530 |
Why?
|
| Age Factors | 15 | 2021 | 775 | 0.520 |
Why?
|
| Biomedical Research | 1 | 2017 | 59 | 0.520 |
Why?
|
| Health Behavior | 2 | 2020 | 160 | 0.520 |
Why?
|
| Double-Blind Method | 12 | 2023 | 407 | 0.510 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 903 | 0.510 |
Why?
|
| Amnesia | 4 | 2011 | 24 | 0.510 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2019 | 309 | 0.490 |
Why?
|
| Hearing | 1 | 2015 | 20 | 0.480 |
Why?
|
| Chicago | 8 | 2019 | 949 | 0.480 |
Why?
|
| Cholinergic Antagonists | 2 | 2021 | 10 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 667 | 0.470 |
Why?
|
| Depressive Disorder, Major | 3 | 2022 | 99 | 0.470 |
Why?
|
| Health Promotion | 1 | 2016 | 144 | 0.470 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 7 | 0.440 |
Why?
|
| Life Style | 4 | 2023 | 186 | 0.440 |
Why?
|
| Central Nervous System Agents | 1 | 2014 | 7 | 0.440 |
Why?
|
| Pyridines | 1 | 2014 | 33 | 0.440 |
Why?
|
| Patient Selection | 2 | 2012 | 197 | 0.430 |
Why?
|
| Treatment Outcome | 6 | 2020 | 3528 | 0.430 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 305 | 0.430 |
Why?
|
| Odds Ratio | 6 | 2020 | 277 | 0.430 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 551 | 0.420 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 44 | 0.420 |
Why?
|
| Adult | 13 | 2022 | 7901 | 0.420 |
Why?
|
| Influenza A virus | 2 | 2018 | 15 | 0.410 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 350 | 0.410 |
Why?
|
| Memory | 6 | 2012 | 295 | 0.390 |
Why?
|
| Automobile Driving | 1 | 2012 | 20 | 0.380 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 1803 | 0.370 |
Why?
|
| Surveys and Questionnaires | 8 | 2021 | 1156 | 0.370 |
Why?
|
| Food | 1 | 2011 | 37 | 0.360 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 892 | 0.360 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 44 | 0.350 |
Why?
|
| Incidence | 12 | 2021 | 762 | 0.350 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 148 | 0.350 |
Why?
|
| Pain | 2 | 2010 | 412 | 0.340 |
Why?
|
| Hippocampus | 4 | 2011 | 276 | 0.330 |
Why?
|
| Neoplasms | 4 | 2021 | 241 | 0.320 |
Why?
|
| Sex Factors | 8 | 2021 | 466 | 0.310 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2019 | 15 | 0.310 |
Why?
|
| Memantine | 2 | 2019 | 9 | 0.310 |
Why?
|
| Memory Disorders | 3 | 2018 | 158 | 0.300 |
Why?
|
| Cognitive Aging | 2 | 2021 | 78 | 0.300 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 53 | 0.290 |
Why?
|
| Quality of Life | 4 | 2021 | 635 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 93 | 0.280 |
Why?
|
| Stroke | 2 | 2023 | 268 | 0.280 |
Why?
|
| Depressive Disorder | 2 | 2019 | 175 | 0.270 |
Why?
|
| Leg | 2 | 2006 | 50 | 0.270 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2012 | 27 | 0.270 |
Why?
|
| Risk Assessment | 7 | 2022 | 629 | 0.270 |
Why?
|
| Adamantane | 1 | 2006 | 1 | 0.270 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 14 | 0.270 |
Why?
|
| Hemorrhage | 4 | 2020 | 82 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 164 | 0.260 |
Why?
|
| Nerve Fibers | 1 | 2006 | 13 | 0.260 |
Why?
|
| Genetic Variation | 2 | 2020 | 97 | 0.250 |
Why?
|
| Apolipoprotein E4 | 6 | 2021 | 265 | 0.250 |
Why?
|
| Antiviral Agents | 1 | 2006 | 71 | 0.250 |
Why?
|
| Amyloid beta-Peptides | 3 | 2018 | 325 | 0.250 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 110 | 0.240 |
Why?
|
| Body Mass Index | 4 | 2021 | 461 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2011 | 1104 | 0.230 |
Why?
|
| Autopsy | 4 | 2020 | 343 | 0.230 |
Why?
|
| Mortality | 3 | 2021 | 93 | 0.220 |
Why?
|
| Clergy | 3 | 2013 | 92 | 0.220 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 129 | 0.220 |
Why?
|
| Disability Evaluation | 5 | 2021 | 266 | 0.220 |
Why?
|
| Prediabetic State | 1 | 2023 | 3 | 0.210 |
Why?
|
| Apolipoproteins E | 5 | 2023 | 253 | 0.210 |
Why?
|
| Influenza, Human | 2 | 2018 | 47 | 0.200 |
Why?
|
| Coronary Disease | 1 | 2023 | 51 | 0.200 |
Why?
|
| Brain Mapping | 4 | 2014 | 149 | 0.200 |
Why?
|
| Primary Prevention | 2 | 2020 | 29 | 0.200 |
Why?
|
| Temporal Lobe | 3 | 2012 | 90 | 0.200 |
Why?
|
| Smoking | 2 | 2018 | 183 | 0.200 |
Why?
|
| Healthy Aging | 1 | 2022 | 14 | 0.190 |
Why?
|
| Radar | 1 | 2022 | 6 | 0.190 |
Why?
|
| Time Factors | 5 | 2018 | 1439 | 0.190 |
Why?
|
| Walking Speed | 1 | 2022 | 42 | 0.190 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 175 | 0.180 |
Why?
|
| Prevalence | 5 | 2020 | 456 | 0.180 |
Why?
|
| Body Weight | 2 | 2020 | 135 | 0.180 |
Why?
|
| Psychomotor Performance | 3 | 2021 | 204 | 0.180 |
Why?
|
| Disease Progression | 5 | 2015 | 673 | 0.180 |
Why?
|
| Sleep Wake Disorders | 2 | 2012 | 122 | 0.170 |
Why?
|
| Databases, Genetic | 1 | 2020 | 8 | 0.170 |
Why?
|
| Antineoplastic Protocols | 1 | 2019 | 1 | 0.170 |
Why?
|
| Mental Status Schedule | 3 | 2018 | 90 | 0.170 |
Why?
|
| Neurons | 2 | 2013 | 340 | 0.170 |
Why?
|
| Verbal Learning | 1 | 2020 | 33 | 0.170 |
Why?
|
| Health Equity | 1 | 2020 | 18 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 13 | 0.160 |
Why?
|
| Genome, Human | 1 | 2020 | 45 | 0.160 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 20 | 0.160 |
Why?
|
| Logistic Models | 5 | 2020 | 397 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2019 | 13 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 34 | 0.160 |
Why?
|
| Terminal Care | 1 | 2019 | 27 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 291 | 0.160 |
Why?
|
| Psychometrics | 2 | 2017 | 221 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2020 | 164 | 0.160 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2018 | 6 | 0.150 |
Why?
|
| Mobility Limitation | 2 | 2012 | 94 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 32 | 0.150 |
Why?
|
| Advisory Committees | 1 | 2018 | 20 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 8 | 0.150 |
Why?
|
| Life Expectancy | 1 | 2018 | 28 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2021 | 61 | 0.150 |
Why?
|
| Parkinsonian Disorders | 2 | 2012 | 225 | 0.150 |
Why?
|
| Regression Analysis | 2 | 2017 | 258 | 0.150 |
Why?
|
| Biomarkers | 3 | 2018 | 559 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2019 | 3542 | 0.150 |
Why?
|
| Education | 1 | 2018 | 39 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 55 | 0.150 |
Why?
|
| Economics | 1 | 2018 | 18 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 46 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 179 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 13 | 0.150 |
Why?
|
| Administration, Oral | 4 | 2018 | 110 | 0.150 |
Why?
|
| Proteome | 1 | 2018 | 41 | 0.150 |
Why?
|
| Social Isolation | 1 | 2018 | 30 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 44 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 24 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 56 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 108 | 0.140 |
Why?
|
| Frail Elderly | 3 | 2022 | 50 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2018 | 115 | 0.140 |
Why?
|
| Proteomics | 1 | 2018 | 88 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2018 | 77 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2018 | 141 | 0.140 |
Why?
|
| Neuropathology | 1 | 2018 | 82 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 224 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 104 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2018 | 416 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 62 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 10 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 115 | 0.140 |
Why?
|
| Selenium | 1 | 2017 | 10 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 11 | 0.140 |
Why?
|
| Internet | 1 | 2018 | 91 | 0.140 |
Why?
|
| Vitamins | 1 | 2017 | 20 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 69 | 0.130 |
Why?
|
| Registries | 1 | 2018 | 193 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 132 | 0.130 |
Why?
|
| Health Literacy | 1 | 2018 | 108 | 0.130 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 54 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 350 | 0.130 |
Why?
|
| Geriatric Assessment | 4 | 2022 | 209 | 0.130 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2021 | 56 | 0.130 |
Why?
|
| Public Health | 1 | 2016 | 71 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2015 | 9 | 0.130 |
Why?
|
| Personality | 2 | 2006 | 53 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2016 | 91 | 0.120 |
Why?
|
| Exosomes | 1 | 2015 | 4 | 0.120 |
Why?
|
| Brain Chemistry | 1 | 2016 | 45 | 0.120 |
Why?
|
| Plasma | 1 | 2015 | 16 | 0.120 |
Why?
|
| Micronutrients | 1 | 2015 | 3 | 0.120 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2015 | 13 | 0.120 |
Why?
|
| Food, Formulated | 1 | 2015 | 5 | 0.120 |
Why?
|
| Auditory Threshold | 1 | 2015 | 21 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2015 | 40 | 0.120 |
Why?
|
| Acoustic Stimulation | 1 | 2015 | 50 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2015 | 65 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2015 | 49 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 124 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2015 | 57 | 0.120 |
Why?
|
| Cerebral Cortex | 2 | 2016 | 153 | 0.110 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2014 | 45 | 0.110 |
Why?
|
| Mesencephalon | 1 | 2013 | 24 | 0.110 |
Why?
|
| Treatment Failure | 3 | 2018 | 159 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 207 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 676 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 38 | 0.110 |
Why?
|
| Glucose | 1 | 2014 | 53 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 50 | 0.110 |
Why?
|
| Exercise | 3 | 2012 | 452 | 0.110 |
Why?
|
| Catholicism | 1 | 2013 | 20 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 88 | 0.110 |
Why?
|
| Comorbidity | 5 | 2018 | 489 | 0.110 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2014 | 115 | 0.100 |
Why?
|
| Psychological Tests | 1 | 2013 | 52 | 0.100 |
Why?
|
| Language Tests | 1 | 2013 | 33 | 0.100 |
Why?
|
| Prognosis | 3 | 2023 | 804 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 161 | 0.100 |
Why?
|
| Educational Status | 3 | 2021 | 290 | 0.100 |
Why?
|
| Perforant Pathway | 1 | 2012 | 3 | 0.100 |
Why?
|
| Spatial Behavior | 1 | 2012 | 9 | 0.100 |
Why?
|
| Licensure | 1 | 2012 | 9 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 3 | 0.100 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 23 | 0.100 |
Why?
|
| Longevity | 1 | 2012 | 31 | 0.100 |
Why?
|
| Environment | 1 | 2012 | 42 | 0.100 |
Why?
|
| HIV Infections | 1 | 2017 | 475 | 0.090 |
Why?
|
| Phlebotomy | 1 | 2011 | 4 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2012 | 100 | 0.090 |
Why?
|
| Anemia | 1 | 2011 | 34 | 0.090 |
Why?
|
| Parahippocampal Gyrus | 1 | 2011 | 6 | 0.090 |
Why?
|
| Entorhinal Cortex | 1 | 2011 | 33 | 0.090 |
Why?
|
| Attention | 1 | 2012 | 124 | 0.090 |
Why?
|
| Sleep Stages | 1 | 2011 | 23 | 0.090 |
Why?
|
| Income | 2 | 2022 | 80 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 344 | 0.090 |
Why?
|
| Young Adult | 4 | 2019 | 2022 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2018 | 589 | 0.090 |
Why?
|
| Corpus Callosum | 1 | 2010 | 13 | 0.080 |
Why?
|
| Atrophy | 2 | 2010 | 87 | 0.080 |
Why?
|
| Substantia Innominata | 1 | 2009 | 5 | 0.080 |
Why?
|
| Neuroimaging | 2 | 2021 | 128 | 0.080 |
Why?
|
| Genotype | 2 | 2012 | 344 | 0.080 |
Why?
|
| Minority Groups | 2 | 2020 | 80 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 331 | 0.070 |
Why?
|
| Medicare | 2 | 2019 | 120 | 0.070 |
Why?
|
| Mental Recall | 1 | 2008 | 62 | 0.070 |
Why?
|
| Health Status | 2 | 2019 | 223 | 0.070 |
Why?
|
| Animals | 2 | 2015 | 3625 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 276 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 478 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 47 | 0.060 |
Why?
|
| Reference Values | 2 | 2020 | 185 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2006 | 34 | 0.060 |
Why?
|
| Urban Health | 1 | 2006 | 23 | 0.060 |
Why?
|
| Cachexia | 1 | 2005 | 12 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 270 | 0.060 |
Why?
|
| Research Design | 2 | 2020 | 186 | 0.060 |
Why?
|
| Postural Balance | 1 | 2006 | 116 | 0.060 |
Why?
|
| tau Proteins | 2 | 2017 | 235 | 0.060 |
Why?
|
| Triglycerides | 1 | 2023 | 62 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 260 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 14 | 0.050 |
Why?
|
| Lewy Bodies | 2 | 2015 | 193 | 0.050 |
Why?
|
| Gait | 1 | 2006 | 411 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2022 | 6 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 109 | 0.050 |
Why?
|
| Polysomnography | 2 | 2012 | 83 | 0.050 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2021 | 12 | 0.050 |
Why?
|
| Organ Size | 2 | 2012 | 95 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2021 | 14 | 0.050 |
Why?
|
| Social Class | 1 | 2021 | 66 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 312 | 0.050 |
Why?
|
| Reaction Time | 1 | 2021 | 102 | 0.050 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2020 | 3 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2020 | 17 | 0.040 |
Why?
|
| Attitude to Death | 1 | 2020 | 12 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 29 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 35 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2020 | 46 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2020 | 54 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2020 | 7 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 5 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 57 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 18 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 623 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 41 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 88 | 0.040 |
Why?
|
| Time | 1 | 2019 | 15 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 31 | 0.040 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 14 | 0.040 |
Why?
|
| Mitochondria | 1 | 2020 | 67 | 0.040 |
Why?
|
| Frontal Lobe | 2 | 2011 | 82 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 240 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 34 | 0.040 |
Why?
|
| Adolescent | 2 | 2018 | 2177 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2020 | 130 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 305 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 15 | 0.040 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 18 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 37 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 218 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2018 | 20 | 0.040 |
Why?
|
| PAX5 Transcription Factor | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 65 | 0.040 |
Why?
|
| India | 1 | 2018 | 17 | 0.040 |
Why?
|
| Gender Identity | 1 | 2018 | 26 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2018 | 26 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 96 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2009 | 103 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2018 | 24 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 368 | 0.040 |
Why?
|
| Vaccination | 1 | 2018 | 35 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 121 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 57 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2017 | 27 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 132 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 84 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 157 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 179 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 524 | 0.030 |
Why?
|
| Personality Assessment | 2 | 2006 | 35 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 275 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 318 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 146 | 0.030 |
Why?
|
| Brain Stem | 1 | 2016 | 19 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 2017 | 195 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 42 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 33 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2015 | 93 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 51 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 143 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2014 | 56 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 9 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 81 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 274 | 0.030 |
Why?
|
| Substantia Nigra | 1 | 2013 | 120 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 25 | 0.020 |
Why?
|
| Visual Cortex | 1 | 2012 | 6 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 56 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 22 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 77 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 94 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 34 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2012 | 53 | 0.020 |
Why?
|
| Genomics | 1 | 2012 | 64 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 77 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1414 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 138 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 119 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 25 | 0.020 |
Why?
|
| Anisotropy | 1 | 2010 | 44 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 208 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 257 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 164 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 39 | 0.020 |
Why?
|
| Bias | 1 | 2006 | 30 | 0.020 |
Why?
|
| Fear | 1 | 2006 | 47 | 0.020 |
Why?
|
| Community Health Services | 1 | 2006 | 34 | 0.020 |
Why?
|
| Social Behavior | 1 | 2006 | 67 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 110 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2006 | 131 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 479 | 0.010 |
Why?
|